IDEXX Laboratories, Inc.

Valuation Analysis

About the Company

IDEXX Laboratories, Inc. en bref

IDEXX Laboratories, Inc. (IDXX) is currently trading at 490,01 € with a market capitalization of 38,7 Md €. The trailing P/E ratio stands at 41.39x, with a forward P/E of 34.03x. The 52-week range spans from 441,91 € to 671,24 €; the current price is 27% below the yearly high. Year-over-year revenue growth stands at +14.3%. The net profit margin stands at 24.63%.

💰 Dividende

IDEXX Laboratories, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent IDEXX Laboratories, Inc. (IDXX) au consensus : Acheter. L'objectif de cours moyen est de 618,20 €, soit un potentiel de +26.16% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 409,73 € à 701,77 €.

IDEXX Laboratories, Inc. : la thèse d'investissement en détail

IDEXX Laboratories, Inc. (IDXX) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 14.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 62.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 72.91% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 3.67, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 29.82x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 34.03x is meaningfully below the trailing 41.39x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 26.16% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to above-average price swings.

Trading Data

Related Stocks in the Same Sector

Where can I buy IDEXX Laboratories, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.